Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer
- Conditions
- Cervical Cancer
- Interventions
- Radiation: fludeoxyglucose F 18Radiation: fluorine F 18 EF5
- Registration Number
- NCT00978874
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Brief Summary
RATIONALE: Diagnostic procedures, such as fluorine F 18 EF5 PET/CT imaging, may help find oxygen in tumor cells. It may also help doctors predict a patient's response to treatment and help plan the best treatment.
PURPOSE: This trial is studying fluorine F 18 EF5 PET/CT imaging to see how well it works in finding hypoxia in tumor cells of patients with locally advanced or recurrent/metastatic cervical cancer.
- Detailed Description
OBJECTIVES:
* To determine if the presence and heterogeneity of hypoxia can be detected by fluorine F 18 EF5 binding in tumors during PET/CT imaging in patients with newly diagnosed or recurrent carcinoma of the cervix.
* To determine if fludeoxyglucose F 18 uptake correlates with fluorine F 18 EF5 uptake.
* To assess the relationship between fluorine F 18 EF5 uptake and disease-free and overall survival.
OUTLINE: Patients are stratified according to disease stage (locally advanced vs recurrent or metastatic disease).
Patients receive fluorine F 18 EF5 IV followed by PET/CT imaging from the base of skull to upper thigh at baseline and during radiotherapy or chemotherapy (i.e., at 3-4 weeks after the initiation of radiotherapy or after the 4th, 5th, or 6th course of chemotherapy). Patients also undergo fludeoxyglucose F 18 PET/CT imaging within 7 to 10 days of the second fluorine F 18 EF5 scan.
After completion of study treatment, patients are followed up at 30 days and then annually thereafter.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 15
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description All subjects fludeoxyglucose F 18 - All subjects fluorine F 18 EF5 -
- Primary Outcome Measures
Name Time Method Relationship Between Fluorine F 18 EF5 Uptake and Disease-free Survival and Overall Survival 7 years The study was terminated and no data are available to be reported
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Abramson Cancer Center of the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States